See the DrugPatentWatch profile for cosentyx
Based on the information provided, it is not explicitly stated that Cosentyx (secukinumab) has failed to improve symptoms. The available information indicates that Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a cytokine involved in the pathogenesis of these conditions [1].
Clinical trials have shown Cosentyx to be effective in improving symptoms of the mentioned conditions. For instance, in a study of patients with moderate-to-severe plaque psoriasis, those treated with Cosentyx showed significant improvement in symptoms compared to placebo [2]. Similarly, in patients with active psoriatic arthritis, Cosentyx was found to significantly improve signs and symptoms of the disease [3].
However, it is important to note that not all patients respond to Cosentyx, and some may experience side effects or lack of symptom improvement. In such cases, patients and healthcare providers may need to consider alternative treatment options.
In conclusion, based on the available information, Cosentyx has demonstrated efficacy in improving symptoms of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in clinical trials. However, individual responses to the medication may vary, and not all patients may experience symptom improvement.
Sources:
[1] Drugs.com. (2021). Cosentyx. Retrieved from <
https://www.drugs.com/cosentyx.html>
[2] Griffiths, C. E., Reich, K., Reich, A., Callis Duffin, K., Blauvelt, A., Gooderham, M., ... & Paul, C. (2015). Comparison of secukinumab and etanercept for treatment of moderate-to-severe plaque psoriasis (ERASER): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet, 385(9986), 2287-2298.
[3] Mease, P. J., McInnes, I. B., Kirkham, B., Kivitz, A., Nash, P., Chatham, W. W., ... & Ritchlin, C. T. (2014). Secukinumab inhibition of interleukin-17A improves signs and symptoms in patients with psoriatic arthritis: the FUTURE 2 study. Annals of the Rheumatic Diseases, 73(11), 1919-1926.